Regenerative medicine company ACell has named a new president and CEO: Patrick McBrayer. McBrayer succeeds Kyle Kerbawy, who will remain as chairman of the board.
McBrayer currently serves on the board of directors of Misonix and was president and CEO of AxioMed Spine Corporation until the company was acquired in 2014. Prior to that, he served as CEO of Xylos Corporation, founded Transave (now Insmed) and served as president and CEO of Exogen.
“ACell’s pioneering technology has immense potential to help people in a wide range of therapeutic areas,” said McBrayer. “I am honored to assume this leadership role, and look forward to working with our board of directors, management and employee teams to advance ACell’s current strategic priorities and develop new opportunities for growth.”
